Overview of Neuromuscular Disorder Molecular Diagnostic Experience for the Population of Latvia.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
12
2021
accepted:
30
03
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Genetic testing has become an integral part of health care, allowing the confirmation of thousands of hereditary diseases, including neuromuscular disorders (NMDs). The reported average prevalence of individual inherited NMDs is 3.7-4.99 per 10,000. This number varies greatly in the selected populations after applying population-wide studies. The aim of this study was to evaluate the effect of genetic analysis as the first-tier test in patients with NMD and to calculate the disease prevalence and allelic frequencies for reoccurring genetic variants. Patients with NMD from Latvia with molecular tests confirming their diagnosis in 2008-2020 were included in this retrospective study. Diagnosis was confirmed in 153 unique cases of all persons tested. Next-generation sequencing resulted in a detection rate of 37%. Two of the most common childhood-onset NMDs in our population were spinal muscular atrophy and dystrophinopathies, with a birth prevalence of 1.01 per 10,000 newborns and 2.08 per 10,000 (male newborn population), respectively. The calculated point prevalence was 0.079 per 10,000 for facioscapulohumeral muscular dystrophy type 1, 0.078 per 10,000 for limb-girdle muscular dystrophy, 0.073 per 10,000 for nondystrophic congenital myotonia, 0.052 per 10,000 for spinobulbar muscular atrophy, and 0.047 per 10,000 for type 1 myotonic dystrophy. DNA diagnostics is a successful approach. The carrier frequencies of the common
Sections du résumé
Background and Objectives
UNASSIGNED
Genetic testing has become an integral part of health care, allowing the confirmation of thousands of hereditary diseases, including neuromuscular disorders (NMDs). The reported average prevalence of individual inherited NMDs is 3.7-4.99 per 10,000. This number varies greatly in the selected populations after applying population-wide studies. The aim of this study was to evaluate the effect of genetic analysis as the first-tier test in patients with NMD and to calculate the disease prevalence and allelic frequencies for reoccurring genetic variants.
Methods
UNASSIGNED
Patients with NMD from Latvia with molecular tests confirming their diagnosis in 2008-2020 were included in this retrospective study.
Results
UNASSIGNED
Diagnosis was confirmed in 153 unique cases of all persons tested. Next-generation sequencing resulted in a detection rate of 37%. Two of the most common childhood-onset NMDs in our population were spinal muscular atrophy and dystrophinopathies, with a birth prevalence of 1.01 per 10,000 newborns and 2.08 per 10,000 (male newborn population), respectively. The calculated point prevalence was 0.079 per 10,000 for facioscapulohumeral muscular dystrophy type 1, 0.078 per 10,000 for limb-girdle muscular dystrophy, 0.073 per 10,000 for nondystrophic congenital myotonia, 0.052 per 10,000 for spinobulbar muscular atrophy, and 0.047 per 10,000 for type 1 myotonic dystrophy.
Discussion
UNASSIGNED
DNA diagnostics is a successful approach. The carrier frequencies of the common
Identifiants
pubmed: 36381256
doi: 10.1212/NXG.0000000000000685
pii: NG2021017316
pmc: PMC9641966
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e685Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7
pubmed: 12206800
Neurology. 2014 Sep 16;83(12):1056-9
pubmed: 25122204
Neuromuscul Disord. 2018 May;28(5):402-407
pubmed: 29606556
J Epidemiol. 2018 Aug 5;28(8):353-360
pubmed: 29576601
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Orphanet J Rare Dis. 2021 Mar 31;16(1):153
pubmed: 33789695
Front Neurol. 2021 Jan 20;11:586610
pubmed: 33551952
Neurology. 2015 Mar 3;84(9):904-11
pubmed: 25653289
Genet Med. 2019 Nov;21(11):2512-2520
pubmed: 31105274
Neurology. 2021 Feb 16;96(7):e1045-e1053
pubmed: 33472919
Orphanet J Rare Dis. 2020 Jun 5;15(1):141
pubmed: 32503598
Int J Neonatal Screen. 2021 May 23;7(2):
pubmed: 34071063
Neurology. 2016 Mar 8;86(10):890-7
pubmed: 26865511
Eur J Neurol. 2019 Mar;26(3):519-524
pubmed: 30351503
Acta Neurol Scand. 1998 Aug;98(2):128-33
pubmed: 9724012
J Med Genet. 2009 Sep;46(9):641-4
pubmed: 19625283
Clin Genet. 2001 May;59(5):344-9
pubmed: 11359466
BMC Musculoskelet Disord. 2016 May 04;17:200
pubmed: 27142102
Orphanet J Rare Dis. 2017 Jul 4;12(1):124
pubmed: 28676062
Orphanet J Rare Dis. 2017 Sep 6;12(1):151
pubmed: 28877744
Brain. 2009 Nov;132(Pt 11):3175-86
pubmed: 19767415
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Ann Hum Genet. 2013 Sep;77(5):435-63
pubmed: 23879295